EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Lymphangioleiomyomatosis: a metastatic lung disease

Nandini Kundu iD, Marina K Holz iD

American Journal of Physiology-Cell Physiology · 01.02.2023 · 324 (2) · C320-C326

DOI: 10.1152/ajpcell.00202.2022 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, erschienen am 01.02.2023. Verfasst von Nandini Kundu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Anatomy, Graduate School of Biomedical Sciences, New York Medical College, Valhalla, New York. Hauptthemen laut MEDLINE: Lymphangioleiomyomatosis, Lung Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, DOD | US Army | MEDCOM | Congressionally Directed Medical Research Programs, HHS | NIH | National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphangioleiomyomatosis (LAM) is a rare disease affecting women, caused by somatic mutations in the TSC1 or TSC2 genes, and driven by estrogen. Similar to many cancers, it is metastatic, primarily to the lung. Despite its monogenetic nature, like many cancers, LAM is a heterogeneous disease. The cellular constituents of LAM are very diverse, including mesenchymal, epithelial, endothelial, and immune cells. LAM is characterized by dysregulation of many cell signaling pathways, distinct populations of LAM cells, and a rich microenvironment, in which the immune system appears to play an important role. This review delineates the heterogeneity of LAM and focuses on the metastatic features of LAM, the deregulated signaling mechanisms and the tumor microenvironment. Understanding the tumor-host interaction in LAM may provide insights into the development of new therapeutic strategies, which could be combinatorial or superlative to Sirolimus, the current U.S. Food and Drug Administration-approved treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphangioleiomyomatosisLung NeoplasmsHumansFemaleTumor Suppressor ProteinsTuberous Sclerosis Complex 2 ProteinLungTumor Microenvironment

Stichwörter der Autor:innen

TSClunglymphangioleiomyomatosismTORrare disease

Substanzen

Tumor Suppressor ProteinsTuberous Sclerosis Complex 2 Protein

Autor:innen und Institutionen

  • Department of Cell Biology and Anatomy, Graduate School of Biomedical Sciences, New York Medical College, Valhalla, New York.
  • Department of Biochemistry and Molecular Biology, Graduate School of Biomedical Sciences, New York Medical College, Valhalla, New York.

ORCID-Profile: Nandini Kundu, Marina K Holz

Förderung

  • NIGMS NIH HHS
  • DOD | US Army | MEDCOM | Congressionally Directed Medical Research Programs
  • HHS | NIH | National Institute of General Medical Sciences

Zitieren

APA

Kundu, N., & Holz, M. K. (2023). Lymphangioleiomyomatosis: a metastatic lung disease. American Journal of Physiology-Cell Physiology, 324(2), C320-C326. https://doi.org/10.1152/ajpcell.00202.2022

Vancouver

Kundu N, Holz MK. Lymphangioleiomyomatosis: a metastatic lung disease. American Journal of Physiology-Cell Physiology. 2023;324(2):C320-C326. doi:10.1152/ajpcell.00202.2022

BibTeX
@article{Kundu2023,
  author = {Kundu, Nandini and Holz, Marina K},
  title = {Lymphangioleiomyomatosis: a metastatic lung disease},
  journal = {American Journal of Physiology-Cell Physiology},
  year = {2023},
  volume = {324},
  number = {2},
  pages = {C320--C326},
  doi = {10.1152/ajpcell.00202.2022}
}
Kostenlos starten →